SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Walter Morton who wrote (1738)11/30/1998 9:16:00 PM
From: Steve Harmon  Read Replies (1) | Respond to of 2742
 
Our shares would be much higher now after the PMC definitive deal was announced originally on Oct. 1. Then that darn TYPO occurred!

But of course more people wanted cheap options....ala ENHANCED!



To: Walter Morton who wrote (1738)12/1/1998 12:47:00 AM
From: Walter Morton  Respond to of 2742
 
CIST offers nine reagents while ENDG offers over 360 reagents. Is there a relationship between product line size and revenue? ENDG seems to be the one stop shop.

I don't think CIST is interested in ENDG's 66 in vitro products. Perhaps they can sell them to VODG.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News